By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celltrion, Inc. 

1000 Marina Boulevard
Suite 200
Brisbane  California  94005  U.S.A.
Phone: N/A Fax:



Company News
Week In Review: Teva (TEVA) Pays $160 Million For US/Canada Rights To Celltrion (068270.KQ) Biosimilars 10/10/2016 9:19:29 AM
Teva (TEVA) Pays $160 Million to Celltrion (068270.KQ) in Biosimilar Hook-Up 10/6/2016 7:03:59 AM
Celltrion (068270.KQ) Announces Its Commitment To Develop Anti-Drug Antibody And Drug Concentration Assay To Enable Evidence-Based Decision-Making In anti-TNF Treatment 7/5/2016 11:23:45 AM Approves Celltrion (068270.KQ)’s INFLECTRA, the First Cheaper Version of Johnson & Johnson (JNJ) Blockbuster Remicade 4/6/2016 6:19:31 AM
FDA’s Arthritis Advisory Committee Recommends Approval Of Celltrion (068270.KQ)’s CT-P13, A Proposed Biosimilar Infliximab, For All Indications 2/10/2016 11:05:25 AM
Johnson & Johnson (JNJ) Falls as FDA Staffers Back Celltrion (068270.KQ)'s Remicade Biosimilar 2/8/2016 6:15:00 AM
Celltrion, Inc. (068270.KQ) And Medidata Team Up To Transform Global Clinical Trials For Biosimilars 1/21/2016 10:39:15 AM
Celltrion, Inc. (068270.KQ): No Difference In Efficacy Or Immunogenicity Following Switch To Remsima®? (Infliximab) From Originator 10/28/2015 10:59:37 AM
Celltrion, Inc. (068270.KQ) Launches World’s First Biosimilar Monoclonal Antibody Remsima In 12 New European Markets 2/25/2015 12:03:28 PM
Celltrion Healthcare: Data Show The World’s First European Medicines Agency-Approved Biosimilar Monoclonal Antibody Remsima Could Reduce Cost Of Treating Crohn’s Disease By Up To €336 Million Over Five Years 2/20/2015 9:04:24 AM